PubMed Health⌕ Search

Biomedical subjects

Y Fradet

Publications and source records attributed to Y Fradet.

103 records · Page 6Linked to original sources
PubMed1984

Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies.

Mouse monoclonal antibodies were obtained by immunization with cultured human bladder cancer or lysates of bladder papilloma. They identify 11 distinct antigenic systems as defined by serological analysis of cultured cells and studies of antigen distribution in normal and neoplastic tissues. The most restricted of these antigens, Om5, defines a subset of bladder tumors. Om5 is not detected in normal bladder urothelium or in any other normal or malignant tissue. T101 and JP165 are also subset markers for bladder cancer that are not detected in normal tissues. T16, T43, T87, and J143 (antigens represented on many cultured cells) are found in specific areas of the normal urinary tract and in a distinctive range of other normal and malignant cell types--e.g., T16 expression in pluristratified epithelium of skin, exocervix, and esophagus. T138 antigen is also a common feature of cultured cell lines, but its expression in sections of normal tissues is restricted to endothelial cells. In contrast, T110 is poorly represented on cultured cells but can be detected in culture supernatants. Localization of T110 in normal tissues showed that it is a component of the extracellular matrix. All determinants detected by this series of antibodies are heat labile and not related to A, B, H, I, Lewis blood group antigens. Six of the antibodies immunoprecipitated glycoproteins from radiolabeled cell lysates: AbT16 (Mrs 48,000 and 42,000), AbT87 (Mr 60,000), AbT43 (Mr 85,000), AbJ143 (Mr 140,000, 120,000, 60,000), AbT43 (Mr 85,000), AbJ143 (Mr 140,000, 120,000, and 30,000), and AbT110 (Mr 240,000).

Antibodies, Monoclonal↗
PubMed1984

Immunoanatomic dissection of the human urinary tract by monoclonal antibodies.

The immunoanatomy of the human kidney and urinary tract has been analyzed by a panel of mouse anti-human monoclonal antibodies that define specific domains and structures. The differentiation antigens detected by these monoclonal antibodies represent a series of glycoproteins characteristic of different cell types. They differ from the blood group antigens and appear to be distinct from other antigens previously described within the kidney or urinary tract. The antigens recognized by these monoclonal antibodies represent an immunohistologic dissection of the human nephron. These antibodies have a broad range of potential applications in studying embryogenesis and pathogenesis of nonneoplastic and neoplastic diseases of the human kidney and urothelium.

Antibodies, Monoclonal↗
PubMed1982

Kidney graft survival: role of blood transfusions and lymphocytotoxic antibodies.

In 121 primary cadaver kidney grafts, a significant increase in graft survival has been observed in recipients transfused prior to transplantation, whatever the number of units received or the time of administration. This beneficial effect of blood transfusion was shown to be independent of the recipient's sex, blood group, HLA-A, B match grade and dialysis time. In longitudinal screenings, the incidence of post-transplant antibodies did not differ according to transfusion status of recipient. However, the graft survival was significantly improved in transfused patients without antibody or with an IgM anti-B (cold) antibody (95% survival at 4 years) as compared to nontransfused with the same characteristics. Patients with IgG anti-B (warm), anti-T or anti-PBL antibodies IgG/IgM shared a uniformly poor graft prognosis whether or not they had been transfused.

Adolescent↗
PubMed1981

Characterization of lymphocytotoxic antibodies in renal transplantation.

Anti-B cell, anti-T cell, and antiperipheral blood lymphocyte antibodies were investigated in the sera from 115 cadaveric kidney graft recipients pre- and post-transplantation. These antibodies were characterized: optimal temperature for cytotoxicity (4 C or 22 C), immunoglobulin class (IgG or IgM), and reactivity after platelet absorption, and thereafter defined according to their influence on the graft survival. Patients with IgM anti-B cell antibodies, reacting mostly at 4 C, the activity of which could not be removed by platelet absorption, have a prognosis of the graft as good as those with no antibody, i.e., the graft function (serum creatinine and severity of rejection) at 3 years was comparable between those two groups. However, when the anti-B cell antibodies unabsorbable on platelets are of IgG class and detected at 4 C and 22 C, the graft outcome is poorer (P less than 0.025 at 3 months). A similar prognosis is observed in patients with antiperipheral blood lymphocyte antibodies of IgG or IgM class, absorbable or not on platelets (P less than 0.05). Lymphocytotoxic antibodies of the IgG class are always associated with a poor graft outcome. On another hand, the cold anti-B cell antibodies of the IgM class are not associated with graft failure but no enhancing effect could be seen.

Adolescent↗
PubMed1981

Influence of HLA-A and HLA-B cross-reactive antigen matching on kidney graft survival.

The presence of cross-reactive (CR) antigens of the HLA-A and B specificities between donor and recipient carries a better graft outcome than an HLA match not taking it into account. This influence of CR antigens has been observed in the case of cadaver kidneys matched only for none or one HLA antigen. If two or more antigens are matched this effect is not seen anymore. This improved graft survival could not be explained on the basis of the number of transfusion nor the incidence of cytotoxic antibodies.

Adolescent↗
PubMedDate not supplied

Cell surface differentiation antigens of normal urothelium and bladder tumors.

Bladder cancer ranks as the third most common malignancy among men and tenth among women. Superficial transitional cell carcinomas (stage Ta, Tis, and T1) account for approximately 70-80% of these tumors, while the remaining 20-30% are invasive (T2, T3, and T4). Approximately 70% of superficial tumors will have one or more recurrences, with 25% of these expressing a higher histologic grade and 10-15% subsequently developing invasive and/or metastatic disease. The detection and prediction of tumor recurrence and/or tumor progression is crucially important if timely and appropriate therapy is to be instituted. Conventional histopathologic evaluation usually provides definitive diagnosis upon which therapeutic planning is based. However, at present there are no more reliable morphologic indicator to identify which individuals will have recurrent disease or who will progress to invasive and/or metastatic cancer. Recent advances in tumor biology have identified markers that are good candidates for clinical applications in early tumor detection, as well as for the stratification of patients with like-appearing morphological lesions with different biological and clinical behavior. The ultimate goal is to develop predictive assays that would segregate patients with high probability of failures versus patients who would be cured by localized modes of therapy.

Antibodies, Monoclonal↗
PubMedDate not supplied

The assessment of disease aggressivity in stage D2 prostate cancer patients (review).

Suppression of androgen levels in blood of stage D2 prostate cancer patients has been the prominent treatment for advanced prostate cancer. However, the duration of hormone sensitivity of prostate tumor is variable. The type of initial response to hormonal treatment, the length of response and patient's survival are in direct association with disease aggressiveness. Recently, an arithmetic formula expressing disease aggressivity was computed using pretreatment values of prostatic acid phosphatase (P.A.P.), alkaline phosphatase (A.P.), degree of tumor differentiation and number of bone metastases. This aggressiveness score was related to disease response and patients outcome receiving hormonal treatments. The use of an arithmetic formula to express disease aggressivity could result in a subdivision of the disease. The identification of the subgroup of stage D2 patients destined not to benefit from hormonal manipulation could change the strategies employed up until today for the treatment of advanced prostate cancer.

Estrogens↗
PubMedDate not supplied

[Modulation of lymphocyte proliferation by serum factors and lipopolysaccharide].

The in vitro proliferative response of rat lymphoctes culitivated in increasing concentrations of calf serm (LCS) was measured by the incorporation of 3H-thymidine. Results showed that in contrast to the response of PHA, the response to concanavlin A (conA) was greatly dependent on the concentration of serum in the medium. Kinetics of the response of ConA indicated that increasing concentrations of LCS unblocked the non-response to supraoptimal doses of the mitogen. The supportive effect of LCS was not due to an increase in cell viability and was abolished when serum was dialyzed. By contrast, lipopolysaccharide (LPS) exerted an adjuvant effect on the response to optimal and suboptimal concentrations of ConA without unblocking the non-response to high doses. LPS facilitated the response to ConA of a distinct subpopulation of T cell isolated by separation on nylon wool columns. This in vitro model allowed us to study some factors which may be implicated in tolerance and immunity.

Animals↗